脑膜瘤的WHO分级、增殖指数和孕激素受体表达因肿瘤位置而异
回顾2006至2016年手术的300例脑膜瘤,重新评估WHO分级、Ki67-MIB1、孕激素受体表达和组织学亚型,并按内侧颅底、外侧颅底、非颅底和椎管内分类比较。结果显示非颅底和外侧颅底脑膜瘤的不典型WHO II型比例、Ki67-Li>4%比例更高,内侧颅底孕激素受体表达≤50%的比例低于非颅底,内侧颅底和椎管内肿瘤体积更小、蛛网膜界面消失比例更低、复发率更低。
要点
- 非颅底和外侧颅底脑膜瘤的WHO II型比例(34%和25.5%)高于内侧颅底(12.5%)和椎管内(7%)(p=0.0003)。
- 非颅底和外侧颅底脑膜瘤的Ki67-Li>4%比例(42%和38%)高于内侧颅底(22%)和椎管内(14%)(p=0.0031)。
- 内侧颅底孕激素受体表达≤50%的比例(25%)低于非颅底(48%)(p=0.009),内侧颅底和椎管内肿瘤复发率更低(p=0.0035)。
核心结论
- 内侧颅底脑膜瘤较外侧颅底和非颅底脑膜瘤体积更小、不典型WHO II型比例更低、Ki67-Li值更低、孕激素受体表达显著更高,对应侵袭性更低和复发率更低。
研究设计与样本
- 回顾性分析2006至2016年手术的300例脑膜瘤,重新评估WHO分级(2007分类)、Ki67-MIB1、孕激素受体表达和组织学亚型,并与肿瘤位置(内侧颅底、外侧颅底、非颅底、椎管内)进行相关性分析。
主要发现
- 非颅底和外侧颅底脑膜瘤的不典型WHO II型比例分别为34%和25.5%,高于内侧颅底的12.5%和椎管内的7%(p=0.0003)。
- 非颅底和外侧颅底脑膜瘤的Ki67-Li>4%比例分别为42%和38%,高于内侧颅底的22%和椎管内的14%(p=0.0031)。
- 内侧颅底脑膜瘤孕激素受体表达≤50%的比例为25%,低于非颅底的48%(p=0.009)。
- 脑膜内皮型和过渡型脑膜瘤更常见于颅底(分别为68.5%和54.5%),纤维型更常见于非颅底(48.5%),砂粒体型更常见于椎管内(50%)(p<0.00001)。
- 内侧颅底和椎管内脑膜瘤较外侧颅底和非颅底脑膜瘤体积更小(p<0.00001)、蛛网膜界面消失比例更低(p=0.0022)、复发率更低(p=0.0035)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Meningiomas may show a different WHO grade and variable biological and clinical behaviors. The aim of the present study is to assess whether WHO grade, proliferation index, progesterone receptor (PR) expression, histological subtype, neuroradiological features, and the recurrence rate differ depending on the tumor location. METHODS: Three hundred meningiomas operated on from 2006 to 2016 were reviewed. The WHO grade (2007 classification), Ki67-MIB1, progesterone receptor expression, and histological subtype were reexamined and correlated to the meningioma location, classified as medial skull base, lateral skull base, non-skull base, and spinal. RESULTS: Non-skull base and lateral skull base meningiomas showed significantly higher rates of atypical WHO II forms (34% and 25.5% respectively) than medial skull base (12.5%) and spinal ones (7%) (p = 0.0003) and also higher rates of tumors with Ki67-Li > 4% (42% and 38% vs 22% and 14%) (p = 0.0031). The rate of meningiomas with PR expression ≤ 50% was significantly lower in medial skull base (25%) than in non-skull base (48%) (p = 0.009). Meningothelial and transitional meningiomas were more frequent at the skull base (68.5% and 54.5%, respectively), the fibroblastic subtype at the non-skull base (48.5%), and the psammomatous at the spinal canal (50%) (p < 0.00001). Medial skull base and spinal meningiomas showed significantly lower size (p < 0.00001), lower rates of cases with lost arachnoid interface (p = 0.0022), and significantly lower recurrence rates (p = 0.0035) than lateral skull base and non-skull base meningiomas. CONCLUSION: Medial skull base meningiomas show lower size, lower rate of atypical forms, lower Ki67-Li values, and significantly higher PR expression than those at the lateral skull base and non-skull base. This corresponds to lesser aggressiveness and lower recurrence rates.
引用
- Maiuri F, Mariniello G, Guadagno E, et al. WHO grade, proliferation index, and progesterone receptor expression are different according to the location of meningioma. Acta Neurochir (Wien). 2019. PMID: 31637512. doi:10.1007/s00701-019-04084-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。